This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heath, J. A. Articles by Trigg, M. E. Search for Related Content PubMed PubMed Citation Articles by Heath, J. A. Articles by Trigg, M. E. Social Bookmarking                            What's this?

Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study

From the Memorial Sloan-Kettering Cancer Center, New York, NY; Children’s National Medical Center, Washington, DC; Mayo Clinic, Rochester, MN; Children’s Hospital Los Angeles, Los Angeles; and Children’s Cancer Group, Arcadia, CA.

Address reprint requests to Peter G. Steinherz, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; email: steinhep{at}mskcc.org.

Purpose: To investigate the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic toxicities, supportive care requirements, time to complete intensive therapy, and event-free survival (EFS) and overall survival (OS) in children with high-risk acute lymphoblastic leukemia (HR-ALL).

Patients and Methods: A total of 287 children with HR-ALL were randomly assigned to intensive chemotherapy regimens (New York I [NY I] or NY II) as part of the Children’s Cancer Group (CCG)-1901 protocol. The induction phases consisted of five drugs (vincristine, prednisone, L-asparaginase, daunorubicin, and cyclophosphamide). Initial consolidation comprised six-agent chemotherapy combined with 18 Gy of total-brain irradiation. Patients were randomly assigned to receive G-CSF (5 µg/kg/day) during either induction or initial consolidation. A crossover study analysis was done on the 259 patients who completed both phases of therapy.

Results: The mean time to neutrophil recovery ( 0.5 x 10⁹/L) was reduced with G-CSF (16.7 v 19.1 days, P = .0003); however, patients who received G-CSF did not have significantly reduced episodes of febrile neutropenia (149 v 164, P = .41), positive blood cultures (57 v 61, P = .66), or serious infections (75 v 79, P = .62). Hospitalization (14.0 v 13.9 days, P = .87) and induction therapy completion times (NY I, 30.3 v 31.3 days, P = .11; NY II, 33.4 v 32.3 days, P = .40) were not significantly altered. There were no differences in 6-year EFS (P = .24) or OS (P = .54) between patients receiving or not receiving G-CSF on CCG-1901, NY I and NY II.

Conclusion: Children with high-risk ALL do not appear to benefit from prophylactic G-CSF.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection Ann Intern Med, September 18, 2007; 147(6): 400 - 411. [Abstract] [Full Text] [PDF]

				A. M. Butturini, F. J. Dorey, B. J. Lange, D. W. Henry, P. S. Gaynon, C. Fu, J. Franklin, S. E. Siegel, N. L. Seibel, P. C. Rogers, et al. Obesity and Outcome in Pediatric Acute Lymphoblastic Leukemia J. Clin. Oncol., May 20, 2007; 25(15): 2063 - 2069. [Abstract] [Full Text] [PDF]

				J. Choi, Y. K. Hwang, K. W. Sung, S. H. Lee, K. H. Yoo, H. L. Jung, H. H. Koo, H.-J. Kim, H. J. Kang, H. Y. Shin, et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia Blood, January 15, 2007; 109(2): 471 - 477. [Abstract] [Full Text] [PDF]

				T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF]

				L. Sung, J. Beyene, J. Hayden, P. C. Nathan, B. Lange, and G. A. Tomlinson A Bayesian Meta-analysis of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in Children with Cancer Am. J. Epidemiol., May 1, 2006; 163(9): 811 - 817. [Abstract] [Full Text] [PDF]

				L. Sung, P. C. Nathan, B. Lange, J. Beyene, and G. R. Buchanan Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., August 15, 2004; 22(16): 3350 - 3356. [Abstract] [Full Text] [PDF]